- Home
- CD vs MNPR Comparison
CD vs MNPR Comparison
Compare CD & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CD | MNPR |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | United States |
| Employees | 13 | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 382.5M | 368.9M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | CD | MNPR |
|---|---|---|
| Price | $4.68 | $69.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $107.00 |
| AVG Volume (30 Days) | ★ 203.2K | 109.2K |
| Earning Date | 08-31-2023 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.99 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.09 | $29.18 |
| 52 Week High | $14.10 | $105.00 |
Technical Indicators
Market Signals| Indicator | CD | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 36.35 | 70.08 |
| Support Level | $4.20 | $56.02 |
| Resistance Level | $6.00 | $76.13 |
| Average True Range (ATR) | 0.96 | 3.19 |
| MACD | -0.24 | 0.70 |
| Stochastic Oscillator | 5.79 | 94.78 |
Price Performance
Historical ComparisonAbout CD Chaince Digital Holdings Inc. Ordinary Shares
Chaince Digital Holdings Inc is digital fintech company providing access to the growing AI-powered infrastructure, blockchain, and digital assets. Its three core business lines include: blockchain and digital asset solutions, AI and HPC infrastructure, developing liquid cooling solutions for AI data centers and comprehensive financial services through Chaince Securities,LLC a FINRA-registered broker-dealer, and RIA.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.